on Dermapharm Holding SE (isin : DE000A2GS5D8)
Dermapharm Holding SE Q1 2026 Financial Performance Report
Dermapharm Holding SE announces its Q1 2026 financial results, showing a consolidated revenue increase of 1.1% year-on-year to EUR 305.8 million. Strong growth in the "Branded pharmaceuticals" segment drove this rise, offsetting the expected decline in the "Parallel import business".
Adjusted EBITDA grew by 7.5% to EUR 87.4 million, reflecting a 28.6% margin. The firm's strategic moves, including the acquisition of the Mucos Group and F. Trenka, bolstered its market position, particularly in inflammation management.
The "Branded pharmaceuticals" segment saw an 11.7% revenue increase, while "Other healthcare products" experienced a slight decline due to business model restructuring. The "Parallel import business" declined by 21.1%, aligning with forecasts.
The Board confirms its 2026 outlook, projecting revenue of EUR 1,182–1,218 million and adjusted EBITDA of EUR 331–341 million.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Dermapharm Holding SE news